Anyra (aflibercept biosimilar) / Zydus Lifesciences - LARVOL DELTA

Zydus Lifesciences has announced the launch of its blockbuster therapy aflibercept biosimilar version in India (The Economic Times) - "The commercial launch is announced following an agreement with the drug’s patent owner Regeneron Pharmaceuticals, and Bayer, according to a company release which did not disclose the deal financial terms. Zydus will market the drug under the brand name Anyra over multiple ophthalmic indication including Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME) and others."

Biosimilar launch • Licensing / partnership • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Edema • Retinal Vein Occlusion

Zydus Life launches ANYRA for advanced eye care, shares react (CNBC-TV18) - "Anyra is indicated for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), along with other ailments."

Biosimilar launch • Retinal Vein Occlusion • Wet Age-related Macular Degeneration